Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Viridian Therapeutics (NASDAQ: VRDN) announced key updates on its thyroid eye disease (TED) program at the ARVO 2023 meeting in New Orleans, running from April 23-27, 2023. A significant aspect includes the oral presentation of Phase 1/2 trial results for its lead candidate VRDN-001, which demonstrated proof-of-concept with notable reductions in proptosis and improved clinical activity scores. Additionally, new preclinical data for VRDN-002 and VRDN-003 will be shared via poster presentations, focusing on pharmacokinetics and safety. The company is progressing VRDN-001 through its Phase 3 THRIVE trial and plans to initiate THRIVE-2 for chronic TED, showcasing a commitment to advancing innovative treatments for this debilitating condition, which affects over 250,000 individuals in the U.S. and Europe.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced the appointment of Tony Casciano as Chief Commercial Officer (CCO) and the departure of Carrie Melvin from her role as Chief Operating Officer (COO). Casciano brings over 20 years of experience in biopharma, including leadership roles at Teal Bio and AMAG Pharmaceuticals. Under his leadership, Viridian aims to strengthen its commercial operation, particularly with its lead asset, VRDN-001, currently in a Phase 3 trial for thyroid eye disease (TED). The company is also pursuing additional therapies for TED. The management transition is seen as a critical step in the company’s growth, as it seeks to deliver novel therapies to underserved populations.
Viridian Therapeutics (Nasdaq: VRDN) announced the approval of non-qualified stock options for 350,000 shares to two new employees, as part of its Inducement Grants, approved by a majority of the independent directors on the Board. These grants, made on March 30 and April 3, 2023, have an exercise price equal to the closing stock price on the Grant Date. They will vest over four years, with 25% vesting after one year, followed by 36 equal monthly installments, contingent on continued employment. The company is advancing treatments for thyroid eye disease, including a Phase 3 trial for VRDN-001, showcasing its commitment to developing medicines for serious and rare diseases.
On March 8, 2023, Viridian Therapeutics (NASDAQ: VRDN) announced its financial results for Q4 and the full year 2022, highlighting notable advancements in its thyroid eye disease (TED) program. The company reported a net loss of $45.8 million for Q4 and $100.9 million for the year, primarily due to increased R&D expenses. They initiated the THRIVE Phase 3 trial for their lead product candidate, VRDN-001, with topline results expected in mid-2024. The firm anticipates initial results from a proof-of-concept study for chronic TED in Q2 2023. Viridian's cash reserves total $424.6 million, sufficient to fund operations into late 2025.
Viridian Therapeutics (NASDAQ: VRDN) has announced presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society from March 11-16, 2023, in Orlando, Florida. Key highlights include an oral presentation of ongoing Phase 1/2 trial data for VRDN-001, targeting thyroid eye disease (TED), scheduled for March 14. Additionally, four poster presentations will cover the clinical and mechanistic findings of their TED pipeline, which aims to improve treatment for patients. The company is advancing VRDN-001 through its THRIVE Phase 3 trial and planning further studies on other pipeline candidates like VRDN-002 and VRDN-003.
Viridian Therapeutics (Nasdaq: VRDN) announced on March 3, 2023, that its Compensation Committee approved the grant of non-qualified stock options for 337,000 shares to three new employees. These grants were made outside of the Amended and Restated 2016 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at the closing stock price on the grant date, with shares vesting over four years. Viridian is focused on developing treatments for serious and rare diseases, particularly advancing its VRDN-001 candidate for thyroid eye disease through both a Phase 3 trial and a Phase 2 proof-of-concept trial.